Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more
a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ARKW | 155.49 | 0.77 | +0.50% |
| ARK Next Generation Internet ETF | |||
| ZNOV | 27.87 | 0.08 | +0.29% |
| Innovator Equity Defined Prt ETF -1YrNov | |||
| NVII | 23.93 | 0.05 | +0.21% |
| REX NVDA Growth & Income ETF | |||
| BSMR | 23.50 | 0.01 | +0.05% |
| Invesco BulletShares 2027 Muncpl Bd ETF | |||
| NMBL | 21.14 | -0.17 | -0.77% |
| NovaTide Flexible Allocation ETF | |||
A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with KALA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then KALA could also see price increases.
| Ticker / NAME | Correlation To AUPH | 1D Price Change % | ||
|---|---|---|---|---|
| AUPH | 100% | -0.06% | ||
| KALA - AUPH | 46% Loosely correlated | +1.69% | ||
| MLTX - AUPH | 45% Loosely correlated | -5.08% | ||
| JSPR - AUPH | 44% Loosely correlated | -5.77% | ||
| VCYT - AUPH | 39% Loosely correlated | -2.76% | ||
| GOSS - AUPH | 37% Loosely correlated | -98.82% | ||
More | ||||
The 10-day RSI Indicator for AUPH moved out of overbought territory on August 21, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUPH as a result. In 78 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for AUPH turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
AUPH broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 61 cases where AUPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
AUPH moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on August 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +12.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 129 of 171 cases where AUPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.483) is normal, around the industry mean (19.994). P/E Ratio (7.059) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (7.047) is also within normal values, averaging (427.627).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.